In this article

JNJ

Follow your favorite stocks CREATE FREE ACCOUNT

Johnson & Johnson said on Tuesday it plans to separate its orthopedics business into a standalone company named DePuy Synthes within the next 18 to 24 months, marking its second major spinoff in two years.

The health-care conglomerate also raised its 2025 sales forecast after reporting quarterly earnings that topped Wall Street expectations.

The company projected product revenue of $93.5 billion to $93.9 billion, about $300 million higher than its prior forecast and above analysts' expectations of $93.4 billion, according to LSEG data.

J&J's orthopedics unit, which makes hip, knee, and shoulder implants, surgical instruments, and other products, generated around $9.2 billion last year, or about 10% of total

See Full Page